Ivan F McMurtry
Overview
Explore the profile of Ivan F McMurtry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
2972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kitagawa A, Jacob C, Jordan A, Waddell I, McMurtry I, Gupte S
J Pharmacol Exp Ther
. 2021 Mar;
377(2):284-292.
PMID: 33758056
Pulmonary hypertension (PH) is a disease of hyperplasia of pulmonary vascular cells. The pentose phosphate pathway (PPP)-a fundamental glucose metabolism pathway-is vital for cell growth. Because treatment of PH is...
2.
Al-Hilal T, Keshavarz A, Kadry H, Lahooti B, Al-Obaida A, Ding Z, et al.
Lab Chip
. 2020 Aug;
20(18):3334-3345.
PMID: 32749432
Currently used animal and cellular models for pulmonary arterial hypertension (PAH) only partially recapitulate its pathophysiology in humans and are thus inadequate in reproducing the hallmarks of the disease, inconsistent...
3.
Joshi S, Kitagawa A, Jacob C, Hashimoto R, Dhagia V, Ramesh A, et al.
Am J Physiol Lung Cell Mol Physiol
. 2020 Mar;
318(4):L773-L786.
PMID: 32159369
Metabolic reprogramming is considered important in the pathogenesis of the occlusive vasculopathy observed in pulmonary hypertension (PH). However, the mechanisms that link reprogrammed metabolism to aberrant expression of genes, which...
4.
Hashimoto R, Lanier G, Dhagia V, Joshi S, Jordan A, Waddell I, et al.
Am J Physiol Lung Cell Mol Physiol
. 2020 Jan;
318(2):L386-L401.
PMID: 31913656
Pulmonary hypertension (PH) is a multicellular and progressive disease with a high mortality rate. Among many cell types, hematopoietic stem cells (HSCs) are incriminated in the pathogenesis of PH. However,...
5.
Oshima K, Crockett E, Joshi S, McLendon J, Matsumoto Y, McMurtry I, et al.
Am J Physiol Lung Cell Mol Physiol
. 2019 Oct;
317(6):L805-L815.
PMID: 31577161
Histological observations in human pulmonary arterial hypertension (PAH) suggest a link between plexiform lesions and pulmonary supernumerary arteries. Pulmonary microvascular endothelial cells are characterized as hyperproliferative and progenitor-like. This study...
6.
Keshavarz A, Alobaida A, McMurtry I, Nozik-Grayck E, Stenmark K, Ahsan F
Mol Pharm
. 2019 Jun;
16(8):3414-3429.
PMID: 31194563
Here, we sought to elucidate the role of CAR (a cyclic peptide) in the accumulation and distribution of fasudil, a drug for pulmonary arterial hypertension (PAH), in rat lungs and...
7.
Rashid J, Nozik-Grayck E, McMurtry I, Stenmark K, Ahsan F
Am J Physiol Lung Cell Mol Physiol
. 2018 Oct;
316(1):L119-L130.
PMID: 30307312
Currently, dual- or triple-drug combinations comprising different vasodilators are the mainstay for the treatment of pulmonary arterial hypertension (PAH). However, the patient outcome continues to be disappointing because the existing...
8.
Rashid J, Alobaida A, Al-Hilal T, Hammouda S, McMurtry I, Nozik-Grayck E, et al.
J Control Release
. 2018 May;
280:113-123.
PMID: 29723610
Peroxisome-proliferator-activated-receptor-gamma (PPAR-γ) is implicated, in some capacity, in the pathogenesis of pulmonary arterial hypertension (PAH). Rosiglitazone, an oral antidiabetic and PPAR-γ agonist, has the potential to dilate pulmonary arteries and...
9.
Zhou C, Crockett E, Batten L, McMurtry I, Stevens T
Am J Physiol Lung Cell Mol Physiol
. 2018 Jan;
314(5):L835-L845.
PMID: 29345199
Here, we tested the hypothesis that severe pulmonary arterial hypertension impairs retrograde perfusion. To test this hypothesis, pulmonary arterial hypertension was induced in Fischer rats using a single injection of...
10.
Hill N, Gillespie M, McMurtry I
Chest
. 2017 Dec;
152(6):1106-1108.
PMID: 29223258
No abstract available.